Objective:

To examine the ethical implications of using placebo-controlled trials in migraine prevention in light of the availability of new effective treatments.

Approach:

• Historical Context: Discusses the historical justification for placebo use in migraine trials when few effective treatments were available.
• Ethical Framework: Analyzes the ethical guidelines governing placebo use, emphasizing changes in the standard of care due to new therapies.
• Standard-of-Care Shift: Explores the shift in migraine prevention standards with the introduction of CGRP-targeting therapies and their implications for trial design.
• Conditions for Placebo Use: Outlines the conditions under which placebo controls are ethically permissible according to major ethical guidelines.

Key Findings:

• The introduction of CGRP-directed therapies has changed the ethical landscape for placebo-controlled trials in migraine prevention.
• Current ethical guidelines restrict placebo use when effective treatments are available, which is now the case in migraine prevention.
• Access to effective treatments varies by region, complicating the ethical justification for placebo use in trials.

Interpretation:

Prolonged placebo exposure in migraine prevention trials is increasingly viewed as ethically avoidable harm due to the availability of effective treatments.

Limitations:

• The analysis may not account for all regional differences in treatment access and ethical considerations.
• The evolving nature of migraine therapies may outpace current ethical guidelines.

Conclusion:

The ethical justification for placebo-controlled trials in migraine prevention is increasingly challenged as effective treatments become standard care.

Sources:

• Declaration of Helsinki
• CIOMS Guidelines